A pharmacogenetic study implicates

Multiple sclerosis (MS) is a disease in which biomarker identification is fundamental to predict response to treatments and to deliver the optimal drug to patients. We previously found an association between rs7298096, a polymorphism upstream to theTo analyse the association between rs7298096 and time to first relapse (TTFR) during IFNβ therapy in MS patients and to better investigate its functional role.Survival analysis was applied in three MS cohorts from different countries (Rs7298096Rs7298096 could influence MS disease activity during IFNβ treatment by modulating